glp-1 and gip medication Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks). For educational comparison only—these are Carolina Aldana NP-PHC, BScN, MN,

Compared to the placebo (-4.0), liraglutide resulted in a greater change in BMI as a percentage of the 95th percentile (-14.0), and an estimated treatment difference of 10.0 (95% CI, 15.1 to 4.8) was observed

Here is a practical approach

Further proteomic analysis revealed that myddosomes include proteins participating in every stage of the TLR pathway and regulate diverse effector responses

Until then the honest summary is: moderate average benefit on insulin need, time in range and weight, a real ketone signal, and a paediatric evidence hole

This way the metabolism is boosted and the fat combustion generating heat over the area treated